Literature DB >> 6420133

Albinism: phenotype or genotype?

D B van Dorp, N J van Haeringen, J W Delleman, P Apkarian, W Westerhof.   

Abstract

As part of a combined ophthalmological, genetic, clinical, biochemical, ultrastructural and electro-physiological study of albinism we have examined over one hundred albinos, together with their heterozygote family members. Given this substantial number, we have developed a diagnostic protocol to facilitate albino classification and heterozygote detection. The major difficulty in the detection and differential diagnosis of albinism is that for a given albino, not all symptoms, either ophthalmological or cutaneous, may be manifest, whereas several may be in a non-albino. To compensate for the wide diversity in albino expression, diagnosis is typically based on the results of combinations of tests.

Mesh:

Substances:

Year:  1983        PMID: 6420133     DOI: 10.1007/bf00154728

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  10 in total

1.  Detection of heterozygotes for tyrosinase-negative oculocutaneous albinism by hairbulb tyrosinase assay.

Authors:  R A King; C J Witkop
Journal:  Am J Hum Genet       Date:  1977-03       Impact factor: 11.025

2.  [A NEW EYE SYNDROME WITH X-CHROMOSOMAL TRANSMISSION. A FAMILY CLAN WITH FUNDUS ALBINISM, FOVEA HYPOPLASIA, NYSTAGMUS, MYOPIA, ASTIGMATISM AND DYSCHROMATOPSIA].

Authors:  H FORSIUS; A W ERIKSSON
Journal:  Klin Monbl Augenheilkd       Date:  1964-04       Impact factor: 0.700

3.  Sex-linked ocular albinism displaying typical fundus changes in the female heterozygote.

Authors:  H F FALLS
Journal:  Am J Ophthalmol       Date:  1951-05       Impact factor: 5.258

4.  Asymmetric visually evoked potentials in human albinos: evidence for visual system anomalies.

Authors:  D Creel; C J Witkop; R A King
Journal:  Invest Ophthalmol       Date:  1974-06

5.  Genetic and biochemical evidence for two forms of oculocutaneous albinism in man.

Authors:  W E Nance; C J Witkop; R F Rawls
Journal:  Birth Defects Orig Artic Ser       Date:  1971-03

6.  Hairbulb tyrosinase activity in oculocutaneous albinism.

Authors:  R A King; C J Witkop
Journal:  Nature       Date:  1976-09-02       Impact factor: 49.962

7.  A decisive electrophysiological test for human albinism.

Authors:  P Apkarian; D Reits; H Spekreijse; D Van Dorp
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1983-05

8.  Autosomal recessive oculocutaneous albinism in man. Evidence for genetic heterogeneity.

Authors:  C J Witkop; W E Nance; R F Rawls; J G White
Journal:  Am J Hum Genet       Date:  1970-01       Impact factor: 11.025

9.  Autosomal recessively inherited ocular albinism. A new form of ocular albinism affecting females as severely as males.

Authors:  F E O'Donnell; R A King; W R Green; C J Witkop
Journal:  Arch Ophthalmol       Date:  1978-09

10.  Classification of albinism in man.

Authors:  C J Witkop; J G White; W E Nance; C E Jackson; S Desnick
Journal:  Birth Defects Orig Artic Ser       Date:  1971-06
  10 in total
  5 in total

1.  The clinical features of albinism and their correlation with visual evoked potentials.

Authors:  S E Dorey; M M Neveu; L C Burton; J J Sloper; G E Holder
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

2.  Congenital nystagmus: a clinical perspective in infancy.

Authors:  S S Gelbart; C S Hoyt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1988       Impact factor: 3.117

3.  Transillumination of iris and subnormal visual acuity--ocular albinism?

Authors:  L Sjödell; A Sjöström; M Abrahamsson
Journal:  Br J Ophthalmol       Date:  1996-07       Impact factor: 4.638

4.  Subnormal visual acuity syndromes (SVAS): albinism in Swedish 12-13-year-old children.

Authors:  A Sjöström; M Kraemer; J Ohlsson; G Villarreal
Journal:  Doc Ophthalmol       Date:  2001-07       Impact factor: 2.379

5.  Subnormal visual acuity (SVAS) and albinism in Mexican 12-13-year-old children.

Authors:  A Sjöström; M Kraemer; J Ohlsson; G Garay-Cerro; M Abrahamsson; G Villarreal
Journal:  Doc Ophthalmol       Date:  2004-01       Impact factor: 2.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.